Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 3 6Phase 1 6Phase NA 5Phase 1/2 1

Status

Terminated 2Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Carcinoma, Renal Cell 20Gastrointestinal Stromal Tumors 9Kidney Neoplasms 6Breast Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Kidney Diseases 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Urologic Neoplasms 1Prostatic Neoplasms 1Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 1Patient Preference 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms by Site 1Gastrointestinal Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Colorectal Neoplasms 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Advanced Renal Cancer 1Adenoma, Islet Cell 1

Interventions

Interferon-alpha 7aldesleukin 6Sunitinib 6Radiotherapy 5Nivolumab 5Doxorubicin 5Vincristine 4Ipilimumab 4Filgrastim 4Dactinomycin 4Chemotherapy, Adjuvant 4Axitinib 4cabozantinib 3Sorafenib 3Everolimus 3Etoposide 3Cyclophosphamide 3temsirolimus 2pembrolizumab 2Ifosfamide 2G250 monoclonal antibody 2Fluorouracil 2Carboplatin 2Bevacizumab 2vitespin 1shark cartilage extract 1pazopanib 1lenvatinib 1glutamic acid diethyl ester 1cemiplimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Kidney Neoplasms × Sunitinib × Clear all
NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

AstraZeneca

Phase 3 Active not recruiting
60 enrolled 15 charts
Genitourinary

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT06726421 2026-01-15

STROKER

Sun Yat-sen University

Phase 3 Recruiting
252 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02684006 2025-07-30

JAVELIN Renal 101

Pfizer

Phase 3 Completed
886 enrolled 37 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT03729245 2023-04-11

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Nektar Therapeutics

Phase 3 Terminated
623 enrolled 14 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00375674 2018-09-21

S-TRAC

Pfizer

Phase 3 Completed
674 enrolled 19 charts
Genitourinary

Kidney Neoplasms

NCT01582672 2018-06-14

ADAPT

Argos Therapeutics

Phase 3 Terminated
462 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡